State & City Reports and Guidance

• Letter to OMH-Licensed Article 31 Mental Health Clinics
• NYS DOH - Opioid Prevention Program: Data to Action Fentanyl-Related Deaths in New York State Outside of New York City, 2015-2017
• NYS DOH Opioid Annual Data Report 2018
• State and Local Policies for OUD
• NYS DOH Opioid Annual Report 2015

Federal Reports and Guidance

• Morbidity and Mortality Weekly Report - Overdose Deaths Involving Fentanyl and Fentanyl Analogs - New York City, 2000-2017
• NCHS Data Brief - CDC Drug Overdose Deaths in US 2017
• The Surgeon General's Spotlight on Opioids 
• National Academies of Sciences, Engineering, and Medicine Opioids Report 2019, Conclusions, & Highlights

Independent Reports

• United Hospital Fund - The Ripple Effect: The Impact of the Opioid Epidemic on Children and Families
• Deaths from Fentanyl, Fentanyl Analogs Have Risen Sharply - Medscape 2018

Peer-Reviewed Research

• Development of a Cascade of Care for Responding to the Opioid Epidemic - Williams et al. Americal Journal of Drug and Alcohol Abuse 2018
• From Risk Reduction to Implementation: Addressing the Opioid Epidemic and Continued Challenges to our Field - Binswanger & Gordon, Substance Abuse 2016

Opioids, Overdose Deaths and Suicide

• Understanding Links Among Opioid Use, Overdose, and Suicide - Bohnert and Ilgen, 2019
• Causes of Death After Nonfatal Opioid Overdose - Olfson et al. JAMA 
• Service Use Preceding Opioid-Related Fatality - Olfson et al. AJP 2018
• Racial Differences in Opioid Overdose Deaths in New York City, 2017 - Allen JAMA Internal Medicine 2019

MAT

• Medications for Alcohol and Opioid Use Disorders and Risk of Suicidal Behavior, Accidental Overdoses and Crime - Molero et al. AJP
• Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association with Mortality - Larochelle et al. Annals of Internal Medicine

Naltrexone and Buprenorphine

• The Next Stage of Buprenorphine Care for Opioid Use Disorder - Martin et al. Annal of Internal Medicine 2018
• Moving Addiction Care to the Mainstream - Improving the Quality of Buprenorphine Treatment - Saloner et al. New England Journal of Medicine 2018
• A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined with Behavioral Therapy, for the Treatment of Opioid Use Disorder - Sullivan et al. AJP 
• Primary Care and the Opioid-Overdose Crisis - Buprenorphine Myths and Realities - New England Journal of Medicine 2018
• Comparative Effectiveness of Extended-Release Naltrexone Versus Buprenorphine-Naloxone for Opioid Relapse Prevention (X:BOT): A Multicentre, Open-Label, Randomised Controlled Trial - Lee et all. 2017
• Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders - Lee et al. New England Journal of Medicine 2016

Substance Use and Mental Disorders

• Co-Occuring Substance Use and Mental Disorders Among Adults with Opioid Use Disorder - Jones & McCance-Katz. Drug and Alcohol Dependence 2019
• Lifetime Comorbidity of DSM-IV Mood and Anxiety Disorders and Specific Drug Use Disorders: Results From the National Epidemiologic Survey on Alcohol and Related Conditions - Conway et al. Journal of Clinical Psychiatry 2006

For more information or questions regarding the Clinic OUD Initiative, please email PSYCKES-Help@omh.ny.gov